MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2026 International Congress

    Responsiveness of Sensor-Derived Measures From a Smartphone-Based Active Typing Test in the Phase 2b LUMA Study of Parkinson’s Disease

    R. Llorens Arenas, E. Bartholome, S. Belachew, C. Bernasconi, G. Cosne, J. Guo, B. Hersh, D. Jennings, A. Juraver, C. Kanzler, A. Karatsidis, M. Pang, ó. Reyes, A. Rodríguez-Romero, M. Wald, P. Wang, M. Yang, C. Mazzà (Cambridge, USA)

    Objective: Investigate the measurement properties of exploratory sensor-derived measures (SDMs) from a smartphone-based typing test in the LUMA study of BIIB122/DNL151 for Parkinson’s disease (PD).…
  • 2026 International Congress

    Responsiveness of a Smartphone-Based Sensor-Derived Composite Endpoint in a Phase 2b Study in Parkinson’s Disease (PD)

    R. Llorens Arenas, E. Bartholome, S. Belachew, C. Bernasconi, G. Cosne, A. Ena, J. Guo, B. Hersh, D. Jennings, A. Juraver, C. Kanzler, A. Karatsidis, F. La Pietra, M. Pang, ó. Reyes, A. Rodríguez-Romero, M. Wald, P. Wang, M. Yang, C. Mazzà (Cambridge, USA)

    Objective: Development of a sensor-derived composite score (CS) for progression of motor symptoms in the LUMA study in PD. Background: LUMA (NCT05348785) is a randomized Phase 2b…
  • 2026 International Congress

    Unraveling Kinase-Phosphatase Dysregulation in Parkinson’s disease Peripheral Blood Mononuclear Cells Through Targeted Transcript Analysis

    E. Basu, R. Banerjee, B. Biswas, S. Mondal, J. Rungta, S. Sengupta, J. Ganguly, D. Dutta, S. Mukherjee, P. Basu, S. Choudhury, H. Kumar (Kolkata, India)

    Objective: To probe kinase-phosphatase dysregulation and peripheral biomarker potential in peripheral blood mononuclear cells (PBMCs) via LRRK2 (kinase), PPM1H and PP2A (phosphatases), LC3 (autophagy), and…
  • 2025 International Congress

    Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial

    K. Fraser, A. Lang, L. Kalia, R. Hauser, J. Greenamyre, Y. Moroishi, J. Kluss, B. Hersh, K. Ferber, R. Maciuca, C. Paián-Ruiz, R. Llorens-Arenas, D. Jennings, S. Huntswork-Rodriguez, D. Graham (Tampa, USA)

    Objective: Evaluate the effects of BIIB122/DNL151 treatment on CSF levels of pRab10, a biomarker of CNS LRRK2 modulation, in a Phase 1 study in healthy…
  • 2025 International Congress

    Impact of Constipation on Motor and Non-Motor Symptoms in G2019s Lrrk2 Parkinson’s Disease A Retrospective Study

    A. Agrebaoui, R. Zouari, A. Mousli, R. Amouri, A. Rachdi, F. Nabli, Z. Saied, S. Ben Sassi (Tunis, Tunisia)

    Objective: This study aimed to investigate the association between constipation and the severity of motor and non-motor symptoms in PD patients with the G2019S LRRK2…
  • 2025 International Congress

    Incidence and Associated Factors for Phenoconversion of Parkinson’s Disease in the Chinese Community Older Adults with LRRK2 G2385R and R1628P Variants

    J. Liu, T. Mi, Z. Gu, Y. Li, M. Cao, Z. Ren, H. Zhang, M. Chen, J. Chen, L. Ma, X. Xu, C. Han, L. Zhang, J. An, P. Chan (Beijing, China)

    Objective: To investigate the 10-year accumulated incidence and associated factors for phenoconversion of Parkinson’s disease (PD) in community older adults carrying LRRK2 G2385R or/and R1628P variants. Background: Previous…
  • 2025 International Congress

    LRRK2 I1371V Mutation Induces ER Stress, Mitochondrial Dysfunction, and Impaired Mitophagy in Parkinson’s Disease Astrocytes

    R. Banerjee, V. Holla, N. Kamble, R. Yadav, P. Pal, I. Datta (Bangalore, India)

    Objective: This study examines the pathogenic effect of the LRRK2 I1371V mutation on mitochondrial dysfunction, as a result of ER calcium dysregulation, and impaired mitophagy…
  • 2025 International Congress

    Distinct roles of PARK2, PINK1, and LRRK2 in neuroinflammation: resistance and susceptibility in immune-mediated mouse models

    D. Cossu, H. Okada, S. Noda, Y. Tomizawa, S. Ueno, L. Sechi, T. Hatano, N. Hattori (Tokyo, Japan)

    Objective: To investigate the impact of PARK2, PINK1, and LRRK2 deficiency on neuroinflammation in aging, using immune-mediated mouse models. Background: Emerging evidence links mitophagy-related genes, including PARK2 (PARKIN), PINK1, and LRRK2, to immune…
  • 2025 International Congress

    LRRK2 Mutation in a Patient with NMDA and GAD 65 Antibodies

    S. Ticehurst Corona, F. García Hernández (Mexico City, Mexico)

    Objective: To describe case of a patient who presented with a history of autoimmune encephalitis with NMDA receptor and GAD 65 antibodies positive in cerebrospinal…
  • 2025 International Congress

    Alterations of Plasma Membrane in Parkinson’s disease LRRK2 I1371V iPSC derived Astrocytes contribute to the vulnerability of the niche cells to Extracellular α-Synuclein

    I. Datta, R. Banerjee, V. Holla, N. Kamble, R. Yadav, P. Pal (Bengaluru, India)

    Objective: This study investigates the impact of LRRK2 I1371V mutation on astrocyte plasma membrane dynamics & its association with extracellular α-synuclein using astrocytes derived from…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 21
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley